Adriano Lazzarin

Overview

Best Publications

• Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

  Francesca J. Torriani;Maribel Rodriguez-Torres;Jürgen K. Rockstroh;Eduardo Lissen

  1717
  Citations

• Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

  Roy T. Steigbigel;David A. Cooper;Princy N. Kumar;Joseph E. Eron

  913
  Citations

• Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.

  Adriano Lazzarin;Bonaventura Clotet;David Cooper;Jacques Reynes

  851
  Citations

• Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

  Jeffrey L. Lennox;Edwin DeJesus;Adriano Lazzarin;Richard B. Pollard

  838
  Citations

• Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

  Adriano Lazzarin;Thomas Campbell;Bonaventura Clotet;Margaret Johnson

  737
  Citations

• Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

  Beatriz Grinsztejn;Bach Yen Nguyen;Christine Katlama;Jose M. Gatell

  736
  Citations

• Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

  Bonaventura Clotet;Nicholas Bellos;Jean Michel Molina;David Cooper

  666
  Citations

• Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

  David A. Cooper;Roy T. Steigbigel;Jose M. Gatell;Jurgen K. Rockstroh

  611
  Citations

• Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial

  Jean Michel Molina;Pedro Cahn;Beatriz Grinsztejn;Adriano Lazzarin

  529
  Citations

• Comparison of Changes in Bone Density and Turnover with Abacavir-Lamivudine versus Tenofovir-Emtricitabine in HIV-Infected Adults: 48-Week Results from the ASSERT Study

  Hans-Jürgen Stellbrink;Chloe Orkin;Jose Ramon Arribas;Juliet Compston

  473
  Citations

• Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.

  Gerd Fätkenheuer;Mark Nelson;Adriano Lazzarin;Irina Konourina

  457
  Citations

• Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials

  Charles B Hicks;Pedro Cahn;David A Cooper;Sharon L Walmsley

  450
  Citations

• The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years

  Mark R. Nelson;Christine Katlama;Julio S. Montaner;David A. Cooper

  448
  Citations

• Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

  Unknown

  428
  Citations

• Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

  Joel Gallant;Adriano Lazzarin;Anthony Mills;Chloe Orkin

  417
  Citations

• Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

  Antonella Castagna;Franco Maggiolo;Giovanni Penco;David Wright

  416
  Citations

• Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system

  P. Cinque;M. Brytting;B. Wahren;A. Linde

  404
  Citations

• Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

  Kathleen Squires;Adriano Lazzarin;José M. Gatell;William G. Powderly

  403
  Citations

• Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

  Joseph J. Eron;Bonaventura Clotet;Jacques Durant;Christine Katlama

  364
  Citations

• Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.

  Margaret Johnson;Beatriz Grinsztejn;Claudia Rodriguez;Jeffrey Coco

  361
  Citations

• The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia

  Giuseppe Pantaleo;James F. Demarest;Timothy Schacker;Mauro Vaccarezza

  357
  Citations

• Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors.

  Marco Ripa;Laura Galli;Andrea Poli;Chiara Oltolini

  355
  Citations

• A Controlled Trial of Zidovudine in Primary Human Immunodeficiency Virus Infection

  Sabine Kinloch De Loës;Bernard J. Hirschel;Bruno Hoen;David A. Cooper

  351
  Citations

• Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial

  Unknown

  164
  Citations